US9750812B2 - Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof - Google Patents

Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof Download PDF

Info

Publication number
US9750812B2
US9750812B2 US13/120,127 US200913120127A US9750812B2 US 9750812 B2 US9750812 B2 US 9750812B2 US 200913120127 A US200913120127 A US 200913120127A US 9750812 B2 US9750812 B2 US 9750812B2
Authority
US
United States
Prior art keywords
composition
finasteride
lipid
acid
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US13/120,127
Other languages
English (en)
Other versions
US20110212167A1 (en
Inventor
Shoukath M. Ali
Ateeq Ahmad
Moghis U. Ahmad
Saifuddin Sheikh
Imran Ahmad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jina Pharmaceuticals Inc
Original Assignee
Jina Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42060413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US9750812(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jina Pharmaceuticals Inc filed Critical Jina Pharmaceuticals Inc
Priority to US13/120,127 priority Critical patent/US9750812B2/en
Assigned to JINA PHARMACEUTICALS, INC. reassignment JINA PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AHMAD, ATEEQ, AHMAD, IMRAN, AHMAD, MOGHIS U., ALI, SHOUKATH M., SHEIKH, SAIFUDDIN
Publication of US20110212167A1 publication Critical patent/US20110212167A1/en
Application granted granted Critical
Publication of US9750812B2 publication Critical patent/US9750812B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • acids include, but are not limited to, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, sulfonic, naphthalene-2-sulfonic, benzenesulfonic acid, and the like.
  • Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
  • active agent-lipid composition for example, finasteride-lipid composition contain cholesterol or cholesterol derivatives.
  • cholesterol derivatives that find use in the present invention include but are not limited to cholesteryl sulfate, cholesteryl hemisuccinate, cholesteryl succinate, cholesteryl oleate, cholesteryl linoleate, cholesteryl eicosapentenoate, cholesteryl linolenate, cholesteryl arachidonate, cholesteryl palmitate, cholesteryl stearate, cholesteryl myristate, polyethylene glycol derivatives of cholesterol (cholesterol-PEG), water soluble cholesterol (for example, cholesterol methyl- ⁇ -cyclodextrin), coprostanol, cholestanol, or cholestane, cholic acid, cortisol, corticosterone or hydrocortisone and 7-dehydrocholesterol.
  • cholesterol derivatives that find use in the present invention include but are not limited to
  • compositions that find use in the present invention include but are not limited to solutions, suspensions, emulsions, ointments; suppositories, gels can be suitable pharmaceutical preparations.
  • active compound-lipid composition for example, finasteride-lipid composition
  • active compound-lipid composition is provided in the form of solutions, gels, oils, and emulsions, such as are known by the addition of suitable water-soluble or water-insoluble excipients, for example polyethylene glycols, certain fats, and esters, compounds having a higher content of polyunsaturated fatty acids and derivatives thereof.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US13/120,127 2008-09-27 2009-09-25 Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof Active 2033-06-27 US9750812B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/120,127 US9750812B2 (en) 2008-09-27 2009-09-25 Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10071408P 2008-09-27 2008-09-27
PCT/US2009/058463 WO2010036947A2 (en) 2008-09-27 2009-09-25 Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof
US13/120,127 US9750812B2 (en) 2008-09-27 2009-09-25 Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof

Publications (2)

Publication Number Publication Date
US20110212167A1 US20110212167A1 (en) 2011-09-01
US9750812B2 true US9750812B2 (en) 2017-09-05

Family

ID=42060413

Family Applications (1)

Application Number Title Priority Date Filing Date
US13/120,127 Active 2033-06-27 US9750812B2 (en) 2008-09-27 2009-09-25 Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof

Country Status (15)

Country Link
US (1) US9750812B2 (enExample)
EP (1) EP2344198B1 (enExample)
JP (3) JP2012504135A (enExample)
CA (1) CA2737025C (enExample)
CY (1) CY1123579T1 (enExample)
DK (1) DK2344198T3 (enExample)
ES (1) ES2834006T3 (enExample)
HR (1) HRP20201860T1 (enExample)
HU (1) HUE052571T2 (enExample)
LT (1) LT2344198T (enExample)
MX (1) MX2011003207A (enExample)
PL (1) PL2344198T3 (enExample)
PT (1) PT2344198T (enExample)
SI (1) SI2344198T1 (enExample)
WO (1) WO2010036947A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220339282A1 (en) * 2018-11-29 2022-10-27 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
US11850300B2 (en) 2022-03-17 2023-12-26 Rally Guide Topical lotion composition, methods of use, and methods of preparation
US12527742B2 (en) 2017-05-30 2026-01-20 Glaxosmithkline Biologicals S.A. Methods for manufacturing a liposome encapsulated RNA
US12533318B2 (en) 2019-08-30 2026-01-27 Glaxosmithkline Biologicals Sa Jet mixing lipid nanoparticle manufacturing process

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2898535C (en) 2008-07-18 2016-05-17 Biomod Concepts Inc. Articles of manufacture releasing an active ingredient
US8691518B2 (en) 2010-09-24 2014-04-08 Global Life Science Partners Limited Systems and methods for predicting response to minoxidil for the treatment of androgenetic alopecia
US10633688B2 (en) 2010-09-24 2020-04-28 Follea International Systems and methods for predicting response to minoxidil for the treatment of androgenetic alopecia
US9588118B2 (en) 2010-09-24 2017-03-07 Follea International Devices for performing colorimetric assay with plucked human hair
ITMI20102165A1 (it) * 2010-11-23 2012-05-24 Medichem Srl Composizione per il lavaggio dei capelli e del cuoio capelluto
PT2702982T (pt) * 2011-04-25 2017-03-17 Park Jun-Hyoung Composição para aplicação tópica para a prevenção da perda de cabelo e estimulação do crescimento capilar
CN104394850A (zh) * 2012-02-16 2015-03-04 布莱特赛德创新有限公司 膳食和营养组合物及应用的方法
WO2013160896A1 (en) * 2012-04-25 2013-10-31 Hadasit Medical Research Services And Development Ltd. Pomegranate oil for preventing and treating neurodegenerative diseases
BR102012022034B1 (pt) * 2012-08-31 2020-02-18 Biolab Sanus Farmacêutica Ltda. Nanopartícula polimérica de finasterida, suspensão aquosa contendo a mesma, composição para tratamento de alopecia, processo de preparação de dita composição, e seu uso
BR102012022036B1 (pt) 2012-08-31 2019-10-01 Biolab Sanus Farmacêutica Ltda. Nanopartícula polimérica de finasterida e minoxidil, processo de sua preparação, suspensão aquosa contendo a mesma, composição farmacêutica, e seu uso
US20150313829A1 (en) * 2012-11-26 2015-11-05 Roberto Queiroga Lautner Topical formulations for the prevention and treatment of alopecia and inhibition of hair growth
HK1222337A1 (zh) * 2013-05-03 2017-06-30 Emollivet Ab 用於施加药物活性成分或化妆品活性成分的局部组合物和载体
KR102317369B1 (ko) 2013-08-15 2021-10-25 마리 케이 인코포레이티드 주름 치료를 위한 국소 피부 조성물
US20150147382A1 (en) * 2013-09-23 2015-05-28 Exir Nano Sina Company Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same
US11660344B2 (en) 2013-11-17 2023-05-30 Medrx Co., Ltd. Transdermal colloidal solution agent
JP6502855B2 (ja) * 2013-11-17 2019-04-17 株式会社 メドレックス 経皮吸収型コロイド液剤
ES2952159T3 (es) 2014-10-29 2023-10-27 Samson Clinical Pty Ltd Minoxidil oral para el tratamiento de alopecia areata
EP3038053B1 (en) 2014-12-22 2019-11-06 Reactive Reality GmbH Method and system for generating garment model data
EP3283045B1 (en) * 2015-04-13 2021-02-17 Fountain Technologies International, LLC One-step method for production of ultra-small lipid structures
WO2016186157A1 (ja) * 2015-05-19 2016-11-24 株式会社メドレックス 経皮吸収型液剤
JP7186093B2 (ja) * 2016-04-19 2022-12-08 ナンヤン テクノロジカル ユニヴァーシティー 前眼部疾患の治療のためのタクロリムスの持続送達用ナノリポソーム
UY37459A (es) 2016-10-28 2018-05-31 Servier Lab Formulación liposomal
FR3066920A1 (fr) * 2017-05-30 2018-12-07 Glaxosmithkline Biologicals S.A. Nouveaux procedes de fabrication d'un adjuvant
CA3069336A1 (en) * 2017-07-12 2019-01-17 Samson Clinical Pty Ltd Promoting hair growth and treatment of hair loss or excessive hair shedding
KR20200079502A (ko) * 2017-10-27 2020-07-03 토피릭스 테라퓨틱스 인코포레이티드 남성 패턴 대머리를 포함하는 피부학적 장애를 치료하기 위한 국소 제형
MX390288B (es) * 2018-02-06 2025-03-20 Centro Int De Cosmiatria S A P I De C V Formulación y método para el tratamiento de la alopecia androgénica.
WO2020097284A1 (en) * 2018-11-08 2020-05-14 Jindal Vinay K TOPICAL FORMULATIONS OF 5-α-REDUCTASE INHIBITORS AND USES THEREOF
US20210353600A1 (en) * 2020-05-12 2021-11-18 Chemistryrx Compositions for treating hair loss
US11311556B2 (en) 2020-05-13 2022-04-26 Varsona Therapeutics, Inc. Topical dutasteride emulsions for treating endocrine therapy-induced alopecia
KR20260009808A (ko) * 2023-04-14 2026-01-20 베이징 지타이 라이프 사이언시스 엘티디 지질 나노입자 조성물 및 이의 용도
WO2025037276A1 (en) * 2023-08-16 2025-02-20 Jina Pharmaceuticals Inc. COMPOSITIONS CONTAINING mTOR INHIBITORS AND LIPIDS

Citations (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0177223A2 (en) 1984-09-24 1986-04-09 Michael Mezei Pharmaceutical multi-phase composition
US4663167A (en) 1984-04-16 1987-05-05 The Board Of Regents Of The University Of Texas System Composition and method for treatment of disseminated fungal infections in mammals
US4761288A (en) * 1984-09-24 1988-08-02 Mezei Associates Limited Multiphase liposomal drug delivery system
US4828837A (en) * 1987-03-30 1989-05-09 Liposome Technology, Inc. Non-crystalline minoxidil composition, its production and application
WO1989005636A1 (en) 1987-12-22 1989-06-29 The Liposome Company, Inc. Spontaneous vesiculation of multilamellar liposomes
WO1990011780A1 (en) 1989-03-31 1990-10-18 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5000887A (en) * 1988-05-17 1991-03-19 Liposome Technology, Inc. Preparation of uniform-size liposomes
US5030442A (en) 1987-03-30 1991-07-09 Liposome Technology, Inc. Non-crystalline minoxidil composition
US5053217A (en) * 1984-03-08 1991-10-01 Phares Pharmaceutical Research Nv Composition and method
WO1992003123A1 (en) 1990-08-28 1992-03-05 Liposome Technology, Inc. Liposome alternative bilayer formulations
GB2256139A (en) 1991-05-30 1992-12-02 Sandoz Ltd Liposome preparations containing terbinafine
EP0285382B1 (en) 1987-04-03 1994-04-13 Merck & Co. Inc. Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
JPH0971513A (ja) 1995-09-07 1997-03-18 Taisho Pharmaceut Co Ltd 育毛剤
US5616334A (en) 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
WO1997012602A1 (en) 1995-10-06 1997-04-10 The Regents Of The University Of Michigan Stimulation of hair follicles
JPH1059829A (ja) 1996-08-13 1998-03-03 Noevir Co Ltd 養毛剤
WO1999061059A1 (en) 1998-05-26 1999-12-02 Taisho Pharmaceutical Co., Ltd. Minoxidil compositions for external use
US6001812A (en) * 1995-04-28 1999-12-14 Societe L'oreal S.A. Modulating body/cranial hair growth with derivatives of the α-type melanocyte-stimulating hormone
WO2000007627A2 (en) 1998-08-04 2000-02-17 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
EP1060732A2 (en) 1999-05-27 2000-12-20 JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. Novel topical formulations comprising vesicle delivery systems
JP2001288090A (ja) 2000-04-07 2001-10-16 Taisho Pharmaceut Co Ltd ミノキシジル含有製剤
WO2001085142A1 (en) 2000-05-05 2001-11-15 Wisconsin Alumni Research Foundation Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
WO2002007728A1 (en) 2000-07-19 2002-01-31 Knowles W Roy Hair loss prevention
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
JP2002308740A (ja) 2001-04-05 2002-10-23 Taisho Pharmaceut Co Ltd ミノキシジル含有製剤
WO2003013245A1 (en) 2001-08-07 2003-02-20 Wisconsin Alumni Research Foundation Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy
US20030039613A1 (en) * 1993-11-30 2003-02-27 Unger Evan C. Novel therapeutic delivery systems
US20030108626A1 (en) 2001-11-01 2003-06-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method and composition for dry eye treatment
US6596266B2 (en) * 2000-02-18 2003-07-22 Natural Science, Inc. Compositions containing minoxidil and saw palmetto for treating baldness
US6733776B1 (en) 1992-04-02 2004-05-11 Anticancer, Inc. Method for promoting hair growth
WO2004060344A2 (en) 2002-12-19 2004-07-22 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20040175417A1 (en) 1990-10-19 2004-09-09 Gilead Sciences, Inc. Amphotericin B liposome preparation
US20040205910A1 (en) 1993-04-02 2004-10-21 Lingna Li Method for promoting hair growth
WO2005000266A2 (en) 2003-05-22 2005-01-06 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
US20050232984A1 (en) * 2002-08-23 2005-10-20 Heinrich Haas Non-vesicular cationic lipid formulations
US6984397B2 (en) * 1999-03-11 2006-01-10 Fujisawa Pharmaceutical Company, Ltd. Liposome preparations
US20060034906A1 (en) * 2004-05-21 2006-02-16 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
WO2006041942A2 (en) 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US20060105968A1 (en) * 2002-10-03 2006-05-18 Cleary John D Compositions comprising highly purified amphotericin b
US7053061B2 (en) * 2000-06-22 2006-05-30 Bharat Serums And Vaccines Limited Amphotercin B structured emulsion
US20070237750A1 (en) * 2004-08-30 2007-10-11 Naughton Gail K Compositions and Methods for Promoting Hair Growth
WO2008038140A2 (en) 2006-06-07 2008-04-03 Foamix Ltd. Foamable vehicle comprising polypropylene glycol alkyl ether and pharmaceutical compositions thereof
US20080248117A1 (en) * 2005-06-09 2008-10-09 Basf Aktiengesellschaft Production of Solid Solutions Based on Poorly-Soluble Active Substances by a Short-Term Heating and Rapid Drying
WO2008127358A2 (en) 2006-10-10 2008-10-23 Jina Pharmaceuticals, Inc. Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof
CN101559038A (zh) 2009-05-21 2009-10-21 江苏黄河药业股份有限公司 非那雄胺的固体脂质纳米粒及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897269A (en) * 1984-09-24 1990-01-30 Mezei Associates Limited Administration of drugs with multiphase liposomal delivery system
FI100692B (fi) * 1994-05-24 1998-02-13 Leiras Oy Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä
US6030948A (en) * 1997-12-19 2000-02-29 Mann; Morris A. Hair regeneration compositions for treatment of alopecia and methods of application related thereto
JP4444385B2 (ja) * 1999-02-25 2010-03-31 帝人株式会社 リポソーム用時調製用キット
DE10036799A1 (de) * 2000-07-28 2002-02-07 Beiersdorf Ag Neues Mittel zur Behandlung der Haare und der Kopfhaut
SE0100374D0 (sv) * 2001-02-07 2001-02-07 Pharmacia Ab Novel compositions of potassium channel openers and protein kinase c inhibitors and use thereof
ES2332584T3 (es) * 2001-03-27 2010-02-09 Phares Pharmaceutical Research N.V. Metodo y composicion para solubilizar un compuesto biologicamente activo con baja solubilidad en agua.
JP2006510733A (ja) * 2002-10-16 2006-03-30 ネオファーム、インコーポレイティッド カルジオリピン分子および合成方法
JP2004155690A (ja) * 2002-11-05 2004-06-03 Shiseido Co Ltd 養毛剤組成物
KR100508019B1 (ko) * 2003-07-19 2005-08-17 한미약품 주식회사 고순도 1-안드로스텐 유도체의 제조 방법
ITMI20032019A1 (it) * 2003-10-17 2005-04-18 Fidia Farmaceutici Microemulsioni di retinoidi e composizioni farmaceutiche che le contengono
US20060239951A1 (en) * 2005-03-30 2006-10-26 Alexandre Valentin Methods for stimulating hair growth by administering BMPs
JP2006290841A (ja) * 2005-04-14 2006-10-26 Nippon Zettoc Co Ltd 化粧料の製造方法および化粧料
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions

Patent Citations (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053217A (en) * 1984-03-08 1991-10-01 Phares Pharmaceutical Research Nv Composition and method
US4663167A (en) 1984-04-16 1987-05-05 The Board Of Regents Of The University Of Texas System Composition and method for treatment of disseminated fungal infections in mammals
JPS6185312A (ja) 1984-09-24 1986-04-30 メゼイ・アソシエイツ・リミテッド 多相リポソーム薬剤送達系
US4761288A (en) * 1984-09-24 1988-08-02 Mezei Associates Limited Multiphase liposomal drug delivery system
EP0177223A2 (en) 1984-09-24 1986-04-09 Michael Mezei Pharmaceutical multi-phase composition
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US5616334A (en) 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US4828837A (en) * 1987-03-30 1989-05-09 Liposome Technology, Inc. Non-crystalline minoxidil composition, its production and application
US5030442A (en) 1987-03-30 1991-07-09 Liposome Technology, Inc. Non-crystalline minoxidil composition
EP0285382B1 (en) 1987-04-03 1994-04-13 Merck & Co. Inc. Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones
WO1989005636A1 (en) 1987-12-22 1989-06-29 The Liposome Company, Inc. Spontaneous vesiculation of multilamellar liposomes
US5000887A (en) * 1988-05-17 1991-03-19 Liposome Technology, Inc. Preparation of uniform-size liposomes
WO1990011780A1 (en) 1989-03-31 1990-10-18 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
WO1992003123A1 (en) 1990-08-28 1992-03-05 Liposome Technology, Inc. Liposome alternative bilayer formulations
US20040175417A1 (en) 1990-10-19 2004-09-09 Gilead Sciences, Inc. Amphotericin B liposome preparation
GB2256139A (en) 1991-05-30 1992-12-02 Sandoz Ltd Liposome preparations containing terbinafine
US6733776B1 (en) 1992-04-02 2004-05-11 Anticancer, Inc. Method for promoting hair growth
US20040205910A1 (en) 1993-04-02 2004-10-21 Lingna Li Method for promoting hair growth
US20030039613A1 (en) * 1993-11-30 2003-02-27 Unger Evan C. Novel therapeutic delivery systems
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US6001812A (en) * 1995-04-28 1999-12-14 Societe L'oreal S.A. Modulating body/cranial hair growth with derivatives of the α-type melanocyte-stimulating hormone
JPH0971513A (ja) 1995-09-07 1997-03-18 Taisho Pharmaceut Co Ltd 育毛剤
WO1997012602A1 (en) 1995-10-06 1997-04-10 The Regents Of The University Of Michigan Stimulation of hair follicles
JPH1059829A (ja) 1996-08-13 1998-03-03 Noevir Co Ltd 養毛剤
EP1080730A1 (en) 1998-05-26 2001-03-07 Taisho Pharmaceutical Co., Ltd Minoxidil compositions for external use
WO1999061059A1 (en) 1998-05-26 1999-12-02 Taisho Pharmaceutical Co., Ltd. Minoxidil compositions for external use
US6284234B1 (en) 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
WO2000007627A2 (en) 1998-08-04 2000-02-17 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
JP2003521452A (ja) 1998-08-04 2003-07-15 ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド 活性薬剤用の局所的供給システム
US6984397B2 (en) * 1999-03-11 2006-01-10 Fujisawa Pharmaceutical Company, Ltd. Liposome preparations
US20020102295A1 (en) 1999-05-27 2002-08-01 Susan Niemiec Compositions for application to the skin or hair
EP1060732A2 (en) 1999-05-27 2000-12-20 JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. Novel topical formulations comprising vesicle delivery systems
US6596266B2 (en) * 2000-02-18 2003-07-22 Natural Science, Inc. Compositions containing minoxidil and saw palmetto for treating baldness
EP1273299A1 (en) 2000-04-07 2003-01-08 Taisho Pharmaceutical Co. Ltd. Minoxidil-containing preparations
JP2001288090A (ja) 2000-04-07 2001-10-16 Taisho Pharmaceut Co Ltd ミノキシジル含有製剤
WO2001085142A1 (en) 2000-05-05 2001-11-15 Wisconsin Alumni Research Foundation Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
US7053061B2 (en) * 2000-06-22 2006-05-30 Bharat Serums And Vaccines Limited Amphotercin B structured emulsion
WO2002007728A1 (en) 2000-07-19 2002-01-31 Knowles W Roy Hair loss prevention
JP2004538243A (ja) 2000-07-19 2004-12-24 ダブリュー・ロイ・ノウルズ 脱毛症の予防
JP2002308740A (ja) 2001-04-05 2002-10-23 Taisho Pharmaceut Co Ltd ミノキシジル含有製剤
WO2003013245A1 (en) 2001-08-07 2003-02-20 Wisconsin Alumni Research Foundation Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy
US20030108626A1 (en) 2001-11-01 2003-06-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method and composition for dry eye treatment
US6656460B2 (en) 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
US20050232984A1 (en) * 2002-08-23 2005-10-20 Heinrich Haas Non-vesicular cationic lipid formulations
US20060105968A1 (en) * 2002-10-03 2006-05-18 Cleary John D Compositions comprising highly purified amphotericin b
WO2004060344A2 (en) 2002-12-19 2004-07-22 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
JP2006514044A (ja) 2002-12-19 2006-04-27 アキュスフィア， インコーポレイテッド 脱凝集微粒子を含む医薬製剤を製造する方法
WO2005000266A2 (en) 2003-05-22 2005-01-06 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
US20060034906A1 (en) * 2004-05-21 2006-02-16 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
US20070237750A1 (en) * 2004-08-30 2007-10-11 Naughton Gail K Compositions and Methods for Promoting Hair Growth
WO2006041942A2 (en) 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
JP2008520547A (ja) 2004-10-04 2008-06-19 キューエルティー ユーエスエー，インコーポレイテッド． 眼部送達のためのポリマー送達処方
US20080248117A1 (en) * 2005-06-09 2008-10-09 Basf Aktiengesellschaft Production of Solid Solutions Based on Poorly-Soluble Active Substances by a Short-Term Heating and Rapid Drying
WO2008038140A2 (en) 2006-06-07 2008-04-03 Foamix Ltd. Foamable vehicle comprising polypropylene glycol alkyl ether and pharmaceutical compositions thereof
WO2008127358A2 (en) 2006-10-10 2008-10-23 Jina Pharmaceuticals, Inc. Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof
CN101559038A (zh) 2009-05-21 2009-10-21 江苏黄河药业股份有限公司 非那雄胺的固体脂质纳米粒及其制备方法

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
Deray et al., "Nephrotoxicite de l'amphotericine B," Nephrologie, 2002, 23(3):119-122.
English Abstract of Deray et al., "Nephrotoxicite de l'amphotericine B," Nephrologie, 2002, 23(3):119-122 (1 page).
English Abstract of JP10-59829 (1 page).
English Abstract of JP2002308740, retrieved Feb. 20, 2014, 1 page.
EP Publication 1080730, published Mar. 7, 2001, is the English language equivalent of WO 99/61059.
EP Publication 1273299, published Jan. 8, 2003, is the English language equivalent of JP2001288090.
EP0177223 is the English equivalent of JP61-85312.
European Search Report for EP Patent Application 09816940.2, mailed Nov. 30, 2012, 7 pages.
Hammarstrom and Smith, "In Vitro Activating Properties of Polyene Antibotics for Murine Lymphocytes," Acta Patho. Microbial. Scand., 1977, 85C(4):277-283.
Medoff and Kobayashi, "Amphotericin B: Old Drug, New Therapy," JAMA, 1975, 232(6):619-620.
Olsen et al., "Topical minoxidil in early male pattern baldness," Journal of the American Academy of Dermatology, 1985, 13:185-192.
Remington's Pharmaceutical Sciences, 15th Edition, 1975, Mack Publishing Company, Easton, PA (TOC Only will provide specific pages upon examiner request).
Roberts, "Androgenetic Alopecia in Men and Women: An Overview of Cause and Treatment," Dermatology Nursing, 1997, 9(6):379-386.
Roberts, "Androgenetic alopecia: Treatment results with topical minoxidil," Journal of the American Academy of Dermatology,1987, 16:705-710.
Sekine et al., New Cosmetics Handbook, Nikko Chemicals, Oct. 30, 2006, pp. 277-282.
U.S. Pat. No. 6,284,234, issued Sep. 4, 2001, is the English language equivalent of JP2003521452.
Valeriote et al., "Protective Effects of Amphotericin B Against Spontaneous and Transplantable Murine Tumors," Journal of the National Cancer Institute, 1976, 56(3):557-560.

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12527742B2 (en) 2017-05-30 2026-01-20 Glaxosmithkline Biologicals S.A. Methods for manufacturing a liposome encapsulated RNA
US20220339282A1 (en) * 2018-11-29 2022-10-27 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
US12551553B2 (en) * 2018-11-29 2026-02-17 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
US12533318B2 (en) 2019-08-30 2026-01-27 Glaxosmithkline Biologicals Sa Jet mixing lipid nanoparticle manufacturing process
US11850300B2 (en) 2022-03-17 2023-12-26 Rally Guide Topical lotion composition, methods of use, and methods of preparation

Also Published As

Publication number Publication date
JP6196943B2 (ja) 2017-09-13
JP2014221784A (ja) 2014-11-27
CA2737025A1 (en) 2010-04-01
US20110212167A1 (en) 2011-09-01
LT2344198T (lt) 2021-02-25
HUE052571T2 (hu) 2021-05-28
PT2344198T (pt) 2020-12-04
JP2017048188A (ja) 2017-03-09
DK2344198T3 (da) 2020-11-30
SI2344198T1 (sl) 2021-01-29
JP2012504135A (ja) 2012-02-16
EP2344198A4 (en) 2013-01-09
CA2737025C (en) 2012-09-04
CY1123579T1 (el) 2022-03-24
WO2010036947A2 (en) 2010-04-01
HRP20201860T1 (hr) 2021-04-16
PL2344198T3 (pl) 2021-05-31
MX2011003207A (es) 2011-11-04
EP2344198B1 (en) 2020-11-04
ES2834006T3 (es) 2021-06-16
EP2344198A2 (en) 2011-07-20
WO2010036947A3 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
US9750812B2 (en) Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof
AU2013371101B2 (en) Sustained-release lipid pre-concentrate of GnRH analogues and pharmaceutical composition comprising the same
US20070077286A1 (en) Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle
EP3845247B1 (en) Use of amino acid based nutrients and pharmaceutical composition containing the same
JP2820688B2 (ja) 極性および中性脂質混合物を含有する胃腸管保護用組成物および胃腸管保護方法
US20110135714A1 (en) Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases
JP2002533379A (ja) 生体内における局所的に非侵襲性である用途のための改善された製剤
TW201124425A (en) Parenteral formulations of gemcitabine derivatives
CN104427977A (zh) 局部麻醉剂的储库制剂及其制备方法
JP2019537565A (ja) 脳波（ｅｅｇ）バーストサプレッションをもたらすために神経ステロイドを投与する方法
IT9067434A1 (it) Procedimento per migliorare l'efficacia terapeutica di corticosteroidi liposolubili e composizione per l'attuazione di tale procedimento
CN102470104B (zh) 含有dha酯的非胃肠道给药的药用组合物
Asl et al. Topical delivery of doxepin using liposome containing cream: An emerging approach in enhancing skin retention.
JP2937135B2 (ja) Ｐｇｅ１含有凍結乾燥製剤及び製法
CN102085186A (zh) 一种甘草次酸乳剂及其制备方法
JP2025506762A (ja) 関節鎮痛用ナノ製剤およびその調製方法並びに用途
WO2014090858A1 (en) Gel compositions
JP2514995B2 (ja) 経皮、経粘膜による物質の吸収を促進する組成物
WO2012122493A1 (en) Lipid based clopidogrel compositions, methods, and uses
TW202417004A (zh) 類固醇激素磷脂組合物及其製備方法
CN121731308A (zh) 包含布瑞哌唑的药物组合物及其药物制剂、制备方法和应用
CN1179721A (zh) 新型药物制剂

Legal Events

Date Code Title Description
AS Assignment

Owner name: JINA PHARMACEUTICALS, INC., ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ALI, SHOUKATH M.;AHMAD, ATEEQ;AHMAD, MOGHIS U.;AND OTHERS;REEL/FRAME:026191/0728

Effective date: 20090602

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 8